<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308931</url>
  </required_header>
  <id_info>
    <org_study_id>2010-012</org_study_id>
    <nct_id>NCT01308931</nct_id>
  </id_info>
  <brief_title>The Effect of Birth Control Methods on Anti-Mullerian Hormone (AMH) Levels</brief_title>
  <official_title>The Effect of Tubal Ligation, Essure Placement, AND Levonorgestrel Intrauterine Device on Serum Anti-Mullerian Hormone Rates Over Time</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Valleywise Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fertility Centers of Arizona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Joseph's Hospital and Medical Center, Phoenix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Valleywise Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve. In&#xD;
      prior studies, tubal ligation has been shown to have an adverse effect on ovarian reserve.&#xD;
      One theory postulated for this effect is that the ovarian circulation is disrupted by the&#xD;
      procedure, leading to altered hormone production. In this prospective cohort study, the&#xD;
      investigators plan to analyze the rates of AMH decline by comparing the following&#xD;
      contraceptive methods: tubal ligation, Essure placement, and levonorgestrel intrauterine&#xD;
      devices (IUDs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-mullerian hormone (AMH) has been shown to be a reliable marker of ovarian reserve&#xD;
      because levels demonstrate a consistent age-related decline and do not fluctuate throughout&#xD;
      the menstrual cycle. In prior studies measuring markers other than AMH, tubal ligation has&#xD;
      been shown to have an adverse effect on ovarian reserve.&#xD;
&#xD;
      The primary aim of this study will be to compare the rates of anti-mullerian hormone (AMH)&#xD;
      decline following tubal ligation, Essure placement, and levonorgestrel IUDs, and then&#xD;
      identifying any and all differences that these specific contraceptive methods have on the&#xD;
      changes of AMH rates over time. The secondary aim will focus on analyzing the various types&#xD;
      of tubal ligation methods (i.e. coagulation, ligation, clips, bands, etc.) to see if&#xD;
      different techniques result in any difference in the rate of AMH decline. The hypothesis is&#xD;
      that tubal ligation will result in an accelerated rate of AMH decline as compared to other&#xD;
      long-term or permanent contraceptive methods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Serum anti-Mullerian hormone levels</measure>
    <time_frame>24 months</time_frame>
    <description>1 blood draw prior to procedure; four more blood draws at 6-month intervals</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Birth Control</condition>
  <arm_group>
    <arm_group_label>Tubal ligation</arm_group_label>
    <description>Patients who elect to have tubal ligation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Essure</arm_group_label>
    <description>Group that elects to have Essure placement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levonorgestrel IUD</arm_group_label>
    <description>Patients that elect to have a levonorgestrel intra-uterine device placement</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women seeking contraceptive methods seen at Maricopa Integrated Health System, Fertility&#xD;
        Centers of Arizona, or St Joseph's Hospital &amp; Medical Center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English-speaking&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Age 25-40&#xD;
&#xD;
          -  Electing one of the following contraceptive methods: tubal ligation, Essure,&#xD;
             levonorgestrel IUD&#xD;
&#xD;
          -  Ability to understand study procedures and to comply with them for the entire length&#xD;
             of the study&#xD;
&#xD;
          -  Willingness to comply with follow-up visit requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;25 or &gt;40 at initiation or completion of the study&#xD;
&#xD;
          -  Prior oophorectomy or salpingectomy&#xD;
&#xD;
          -  Prior surgery of the ovaries or fallopian tubes&#xD;
&#xD;
          -  Prior ovarian, uterine, or fallopian tube cancers&#xD;
&#xD;
          -  Prior ovarian, uterine, or fallopian tube radiation exceeding &gt;200rads&#xD;
&#xD;
          -  Prior platinum-based or alkalizing chemotherapy&#xD;
&#xD;
          -  Current cancer (any form)&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  Allergy to any of the components of the selected devices (titanium, rubber, nickel,&#xD;
             plastic, silicone)&#xD;
&#xD;
          -  Current drug or alcohol use or dependence that, in the opinion of the site&#xD;
             investigator, would interfere with adherence to study requirements&#xD;
&#xD;
          -  Inability or unwillingness of a potential participant to give written informed consent&#xD;
&#xD;
          -  Inability for the potential participant to consent for herself&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel F Rychlik, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maricopa Integrated Health System/Fertility Centers of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maricopa Integrated Health System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph's Hospital &amp; Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fertility Centers of Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005 Apr;83(4):979-87.</citation>
    <PMID>15820810</PMID>
  </results_reference>
  <results_reference>
    <citation>Goynumer G, Kayabasoglu F, Aydogdu S, Wetherilt L. The effect of tubal sterilization through electrocoagulation on the ovarian reserve. Contraception. 2009 Jul;80(1):90-4. doi: 10.1016/j.contraception.2008.12.012. Epub 2009 Mar 6.</citation>
    <PMID>19501222</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>March 2, 2011</study_first_submitted>
  <study_first_submitted_qc>March 3, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2011</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraception</keyword>
  <keyword>IUD</keyword>
  <keyword>Essure</keyword>
  <keyword>Tubal ligation</keyword>
  <keyword>Anti-Mullerian hormone</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

